Indication
Atypical Hemolytic Uremic Syndrome (aHUS)
3 clinical trials
2 products
Product
RavulizumabClinical trial
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)Status: Completed, Estimated PCD: 2022-12-20
Clinical trial
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)Status: Completed, Estimated PCD: 2023-01-24
Clinical trial
Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH StudyStatus: Terminated, Estimated PCD: 2021-12-07
Product
Eculizumab